157 related articles for article (PubMed ID: 24393931)
21. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
[TBL] [Abstract][Full Text] [Related]
22. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
[TBL] [Abstract][Full Text] [Related]
23. Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation.
Zhu K; Huang J; Lai L; Huang W; Cai M; Zhou J; Guo Y; Chen J
Radiology; 2018 Jul; 288(1):300-307. PubMed ID: 29688153
[TBL] [Abstract][Full Text] [Related]
24. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
Geschwind JF; Kudo M; Marrero JA; Venook AP; Chen XP; Bronowicki JP; Dagher L; Furuse J; Ladrón de Guevara L; Papandreou C; Sanyal AJ; Takayama T; Ye SL; Yoon SK; Nakajima K; Lehr R; Heldner S; Lencioni R
Radiology; 2016 May; 279(2):630-40. PubMed ID: 26744927
[TBL] [Abstract][Full Text] [Related]
25. Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
Zhong BY; Ni CF; Chen L; Zhu HD; Teng GJ
Radiology; 2017 Aug; 284(2):583-592. PubMed ID: 28263701
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib combined with TACE in advanced primary hepatocellular carcinoma.
Cui HZ; Dai GH; Shi Y; Chen L
Hepatogastroenterology; 2013; 60(122):305-10. PubMed ID: 23574656
[TBL] [Abstract][Full Text] [Related]
27. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
[No Abstract] [Full Text] [Related]
28. Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Oncology; 2014; 87 Suppl 1():32-6. PubMed ID: 25427731
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
30. Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
Yao X; Yan D; Zeng H; Liu D; Li H
J Surg Oncol; 2016 May; 113(6):672-7. PubMed ID: 26989044
[TBL] [Abstract][Full Text] [Related]
31. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
[TBL] [Abstract][Full Text] [Related]
32. Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
Bettinger D; Spode R; Glaser N; Buettner N; Boettler T; Neumann-Haefelin C; Brunner TB; Gkika E; Maruschke L; Thimme R; Schultheiss M
BMC Gastroenterol; 2017 Aug; 17(1):98. PubMed ID: 28797231
[TBL] [Abstract][Full Text] [Related]
33. [Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis].
Chen JW; Pang PF; Meng XC; Zhou B; Huang WS; Guo YJ; Zhu KS; Shan H
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(9):663-7. PubMed ID: 23751743
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization].
Shiozawa K; Watanabe M; Ikehara T; Matsukiyo Y; Kogame M; Okano N; Kikuchi Y; Igarashi Y; Sumino Y
Gan To Kagaku Ryoho; 2015 Aug; 42(8):953-6. PubMed ID: 26321708
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.
Ohki T; Sato K; Yamagami M; Ito D; Yamada T; Kawanishi K; Kojima K; Seki M; Toda N; Tagawa K
Clin Drug Investig; 2015 Nov; 35(11):751-9. PubMed ID: 26446004
[TBL] [Abstract][Full Text] [Related]
36. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
[TBL] [Abstract][Full Text] [Related]
37. Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
Cabibbo G; Tremosini S; Galati G; Mazza G; Gadaleta-Caldarola G; Lombardi G; Antonucci M; Sacco R
Expert Rev Anticancer Ther; 2014 Jul; 14(7):831-45. PubMed ID: 24850249
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
Hua XD; He ZY
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):790-2. PubMed ID: 23291076
[TBL] [Abstract][Full Text] [Related]
40. Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
Schmidt L; op den Winkel M; Fischer K; Straub G; Rauch B; Paprottka PM; Göke B; Kolligs FT
Digestion; 2014; 90(4):219-28. PubMed ID: 25502689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]